Journal of Life Science (생명과학회지)

Korean Society of Life Science (한국생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Berberine on the Proinflammatory Cytokines Production in Mice

베르베린이 마우스 전염증성 사이토카인의 생성에 미치는 영향

  • Chung, Su-Ryoung (Department of Internal Medicine, Dong Eui Medical Center, Dong Eui University) ;
  • Choi, Myung-Won (Department of Microbiology, Kosin University College of Medicine) ;
  • Park, In-Dal (Department of Microbiology, Kosin University College of Medicine) ;
  • Kim, Kwang-Hyuk (Department of Microbiology, Kosin University College of Medicine)
  • 정수룡 (동의대학교 동의의료원 내과) ;
  • 최명원 (고신대학교 의과대학 미생물학교실) ;
  • 박인달 (고신대학교 의과대학 미생물학교실) ;
  • 김광혁 (고신대학교 의과대학 미생물학교실)
  • Received : 2010.07.29
  • Accepted : 2010.08.19
  • Published : 2010.08.30
Download PDF
⟨ Previous Next ⟩

Abstract

Berberine has shown a number of beneficial effects, including anti-tumor, anti-inflammation, and vasodilatory effects. In this work we investigated the effects of berberine on the production of proinflammatory cytokines such as TNF-$\alpha$, IL-$1{\beta}$, and IL-6 in mice. The supernatants of cultured splenocytes exposed with berberine or berberine plus LPS were harvested to assay TNF-$\alpha$, IL-$1{\beta}$, and IL-6. The sera from the mice injected with berberine or berberine plus LPS were then isolated to assay these cytokines. The TNF-$\alpha$ production in mice splenocyte cultures exposed to berberine was inhibited compared to the PBS control. The sera from LPS plus berberine injected mice showed lower levels of TNF-$\alpha$ compared to those of LPS only injected mice. The IL-$1{\beta}$ production in mice splenocyte cultures exposed to berberine was inhibited at a high dose (3.0 ${\mu}g/ml$) compared to the PBS control. Also, the increase of IL-$1{\beta}$ by LPS exposure in splenocyte cultures was inhibited by a high dose of berberine. The IL-6 in splenocyte culture supernatants showed lower levels after berberine compared to the PBS control. Also, production of IL-6 after LPS exposure in splenocyte cultures was inhibited by a low dose of berberine (0.3 ${\mu}g/ml$). These findings suggest the probability that berberine down-regulates the production of proinflammatory cytokines such as TNF-$\alpha$, IL-$1{\beta}$, and IL-6.

본 연구에서는 berberine이 전염증성사이토카인의 생성에 미치는 효과를 관찰하기 위하여 TNF-$\alpha$, IL-$1{\beta}$, 그리고 IL-6생성을 정량하였다. 마우스 비장세포에 berberine을 작용시켰을 때 TNF-$\alpha$의 생성이 억제되었다. 또한 마우스 생체 내에서 LPS에 의한 TNF-$\alpha$의 상승이 berberine에 의해서 억제됨을 알 수 있었다. IL-$1{\beta}$의 생성에 있어서도 berberine을 고농도(3.0 ${\mu}g/ml$)로 작용시켰을 때 억제되었고 LPS에 의한 IL-$1{\beta}$의 상승이 고농도의 berberine에 의해서 억제되었다. IL-6의 생성은 berberine에 의해서 억제되었으며 낮은 berberine 농도(0.3 ${\mu}g/ml$)에서 LPS에 의한IL-6의 생성이 억제되었다. 따라서 이러한 결과들은 berberine이 TNF-$\alpha$, IL-$1{\beta}$, 그리고 IL-6와 같은 전염증성사이토카인의 생성을 하향 조절할 가능성을 시사한다 하겠다.

Keywords

References

  1. Anis, K. V., N. V. Rajeshkumar, and R. Kuttan. 2001. Inhibition of chemical carcinogenesis by berberine in rat and mice. J. Pharm. Pharmacol. 53, 763-768. https://doi.org/10.1211/0022357011775901
  2. Creasey, W. A. 1979. Biochemical effects of berberine. Biochem. Pharmacol. 28, 1081-1084. https://doi.org/10.1016/0006-2952(79)90308-3
  3. Iizuka, N., K. Miyamoto, K. Okita, A. Tangoku, H. Hayashi, S. Yoshino, T. Abe, T. Morioka, S. Hazama, and M. Oka. 2000. Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Lett. 148, 19-25. https://doi.org/10.1016/S0304-3835(99)00264-5
  4. Iizuka, N., K. Miyamoto, S. Hazama, S. Yoshino, K. Yoshimura, K. Okida, T. Hukumoto, S. Yamamoto, A. Tangoku, and M. Oka. 2000. Anticachectic effect of Coptidis rhizoma, an antiinflammatory herb, on esophageal cancer cells that produce interleukin 6. Cancer Lett. 158, 35-41. https://doi.org/10.1016/S0304-3835(00)00496-1
  5. Ikram, M. 1975. A review on the chemical and pharmacological aspects of genus Berberis. Planta Med. 28, 353-358. https://doi.org/10.1055/s-0028-1097869
  6. Ivanovska, N. and S. Phillip. 1996. Study on the anti-inflammatory of Berveris vulgaris root extract, alkaloid fractions and pure alkaloids. Int. J. Immunopharmacol. 18, 553-561. https://doi.org/10.1016/S0192-0561(96)00047-1
  7. Jantova, S., L. Cipak, M. Cernakova, and D. Kost'alova. 2003. Effect of berberine on proliferation, cell cycle and apoptosis in HeLa and L1210 cells. J. Pharm. Pharmacol. 55, 1143-1149. https://doi.org/10.1211/002235703322277186
  8. Kallapur, S. G. and A. H. Jobe. 2006. Contribution of inflammation to lung injury and development. Arch. Dis. Child. Fetal Neonatal. 91, 132-135. https://doi.org/10.1136/adc.2004.068544
  9. Kettmann, V., D. Kosfalova, S. Jantova, M. Cernakova, and J. Drimal. 2004. In vitro cytotoxicity of ververine against HeLa and L1210 cancer cell lines. Pharmazie 59, 548-551.
  10. Kim, S. M., Y. Kim, J. E. Kim, K. H. Cho, and J. H. Chung. 2008. Berberine inhibits TPA-induced MMP-9 and IL-6 expression in normal human keratinocytes. Phytomedicine 15, 340-347. https://doi.org/10.1016/j.phymed.2007.09.011
  11. Kong, W. J., Z. Y. Zuo, Y. M. Wang, D. Q. Song, X. F. You, L. X. Zhao, H. N. Pan, and J. D. Jiang. 2008. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metab. Clin. Exp. 57, 1029-1037. https://doi.org/10.1016/j.metabol.2008.01.037
  12. Kuo, C. L., C. W. Chi, and T. Y. Liu. 2004. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 203, 127-137. https://doi.org/10.1016/j.canlet.2003.09.002
  13. Lau, C. W., X. Q. Yao, Z. Y. Chen, W. H. Ko, and Y. Huang. 2001. Cardiovascular actions of berberine. Cardiovasc. Drug Rev. 19, 234-244. https://doi.org/10.1111/j.1527-3466.2001.tb00068.x
  14. Lee, C. H., J. C. Chen, C. Y. Hsiang, S. L. Wu, H. C. Wu, and T. Y. Ho. 2007. Berberine suppresses inflammatory agents-induced interleukin-1$\beta$ and tumor necrosis factor-$\alpha$ productions via the inhibition of I$\kappa$B degradation in human lung cells. Pharmacol. Res. 56, 193-201. https://doi.org/10.1016/j.phrs.2007.06.003
  15. Liu, Y., H. Yu, C. Zhang, Y. Cheng, L. Hu, X. Meng, and Y. Zhao. 2008. Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer. Eur. J. Cancer 44, 2425-2432. https://doi.org/10.1016/j.ejca.2008.07.040
  16. Marinova, E. K., D. B. Nikolova, D. N. Popova, G. B. Gallacher, and N. D. Ivanovska. 2000. Suppression of experimental autoimmune tubulointerstitial nephritis in BALB/C mice by berberine. Immunopharmacol. 48, 9-16. https://doi.org/10.1016/S0162-3109(99)00189-7
  17. Shvarev, I. F. and A. L. Tsetlin. 1972. Anti-blastic properties of berberine and its derivatives. Farmakol. Toksikol. 35, 73-75.
  18. Sun, Y., K. Xun, Y. Wang, and X. Chen. 2009. A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anticancer Drugs 20, 757-769. https://doi.org/10.1097/CAD.0b013e328330d95b
  19. Xu, Y., Y. Wang, and L. Yan. 2009. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation. J. Proteome Res. 8, 5296-5304. https://doi.org/10.1021/pr9005074
  20. Yin, J., H. L. Xing, and J. P. Ye. 2008. Efficacy of berberine in patients with type 2 diabetes mellitus. Metab. Clin. Exp. 57, 712-717. https://doi.org/10.1016/j.metabol.2008.01.013
  21. Yu, H. H., K. J. Kim, J. D. Cha, H. K. Kim, Y. E. Lee, N. Y. Choi, and Y. O, You. 2005. Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. J. Med. Food 8, 454-461. https://doi.org/10.1089/jmf.2005.8.454
  22. Zhao, W., Z. X. Zhou, W. J. Kong, and J. D. Jiang. 2008. Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomed. Pharmacother. 62, 730-731. https://doi.org/10.1016/j.biopha.2008.01.007